Photo from Unsplash
Originally Posted On: https://yutiq.com/discover-continuous-calm-in-uveitis/
Discover CONTINUOUS CALM
in Uveitis
Interrupted routines, frequent doctor visits, and unpredictable flare-ups can take a toll on the lives of those with uveitis. When considering uveitis treatment options, the YUTIQ® fluocinolone acetonide (0.18 mg) implant stands out as the only injectable treatment option for chronic non-infectious uveitis affecting the posterior segment (NIU-PS).
Unlike many other treatments, which require frequent injections to keep the symptoms of inflammation under control, YUTIQ may reduce flare-ups, which are the recurrence of inflammation, for up to three years with a single injection. Only YUTIQ offers patients CONTINUOUS CALM with fewer treatments for their chronic non-infectious uveitis affecting the back of the eye.
Understanding CONTINUOUS CALMTM
How does such a tiny implant make such a big impact in managing chronic NIU-PS? What sets YUTIQ apart is its ability to deliver a sustained release of fluocinolone acetonide (FAc) for up to 36 months with CONTINUOUS MICRODOSING Technology. FAc treats the inflammation associated with chronic NIU-PS.
Unlike other steroids that often require frequent injections, YUTIQ offers long-lasting treatment with a single injection. It works diligently inside the eye, precisely where it’s needed, offering targeted treatment for indicated types of uveitis for up to 36 months. That’s one injection that may provide CONTINUOUS CALM with less inflammation and flare-ups, offering better vision, longer, with fewer treatments.
The Impact on Patient Lives
Patients treated with YUTIQ may experience reduced uveitis flare-ups and fewer treatment appointments. Strong clinical trial evidence demonstrated improvements in visual acuity and swelling in the back of the eye while reducing the recurrence of inflammation and treatment burden in most patients. This may mean fewer disruptions caused by flare-ups and more time for what truly matters.*
The journey toward better vision and reduced treatment burden continues to evolve, offering a brighter outlook for those dealing with the challenges of NIU-PS. To learn more about YUTIQ and its ability to deliver CONTINUOUS CALM, please visit our website.
*YUTIQ was assessed in two randomized, multicenter, sham-controlled, double-masked, Phase III clinical trials in adult patients [N=282] with chronic noninfectious uveitis affecting the posterior segment of the eye. In the two clinical trials, YUTIQ-treated patients had 67% and 45% fewer recurrences than control patients by 12 months. YUTIQ-treated patients gained over six letters more than control patients by three years. YUTIQ-treated patients had about a third as many adjunctive treatments than control patients by three years.
